Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

JAK2V617F mutation in patients with thrombosis: to screen or not to screen?

International journal of laboratory hematology - 1 Apr 2011

Xavier S G, Gadelha T, Rezende S M, Zalcberg I R, Spector N

Abstract excerpt

INTRODUCTION: Thrombotic complications are a main concern in patients with myeloproliferative neoplasms. Recently, a gain-of-function mutation of the gene encoding the JAK2 tyrosine kinase that results in a valine-to-phenylalanine substitution at position 617 (V617F) has been described. Since the description of the JAK2-V617F mutation and its finding in patients with splanchnic vein thrombosis without an overt...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to JAK2 gene
Share to Genetic Predisposition to Disease
Share to Genetic Testing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Janus Kinase 2

Share to Mutation

Share to Myeloproliferative Disorders

Share to Myeloproliferative Neoplasms: Diagnosis and Treatment

Share to Thrombosis

Source

Identifiers

PMID: 21118380
DOI: 10.1111/j.1751-553X.2010.01275.x

Genes

JAK2

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

JAK2V617F mutation in patients with thrombosis: to screen or not to screen?PMID 21118380Read ↗

The JAK2 V617F mutation in patients with cerebral venous thrombosis.Semantic proximity Read ↗

Should We Screen for Janus Kinase 2 V617F Mutation in Cerebral Venous Thrombosis?Semantic proximity Read ↗

Is the JAK2 V617F mutation a hallmark for different forms of thrombosis?Semantic proximity Read ↗

Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders.Semantic proximity Read ↗

Low prevalence of JAK2 V617F mutation in patients with thrombosis and normal blood counts: a retrospective impact study.Semantic proximity Read ↗

JAK2 mutations across a spectrum of venous thrombosis cases.Semantic proximity Read ↗

JAK2V617F mutation screening as part of the hypercoagulable work-up in the absence of splanchnic venous thrombosis or overt myeloproliferative neoplasm: assessment of value in a series of 664 consecutive patients.Semantic proximity Read ↗

JAK2V617F mutation in patients with splanchnic vein thrombosis.Semantic proximity Read ↗

[Thrombosis in myeloproliferative neoplasms].Semantic proximity Read ↗

Prevalence of overt myeloproliferative neoplasms and JAK2 V617F mutation in Korean patients with splanchnic vein thrombosis.Semantic proximity Read ↗

Prevalence of Janus Kinase 2 mutations in patients with unusual site venous thrombosis.Semantic proximity Read ↗

Cerebral venous sinus thrombosis associated with JAK2 V617F mutation-related pre-primary myelofibrosis: a case report and literature review.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.